The neurochemistry and neuropharmacology of frontotemporal dementia;Neuroquímica y neurofarmacología de la demencia frontotemporal

Revista de Neurologia

Volumn 42, Issue 9, 2006, Pages 556-561

  Alonso Navarro, H ^a   Jabbour Wadih, T ^a   Ayuso Peralta, L ^a   Jimenez Jimenez F J ^a,b  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b NONE   (Spain)

Author keywords

Frontotemporal dementia; Functional neuroimaging; Neurochemistry; Neuropharmacology; Oxidative stress; Serotoninergic system

Indexed keywords

NEUROTRANSMITTER; DOPAMINE; GLUCOSE; SEROTONIN;

ALZHEIMER DISEASE; APOPTOSIS; BRAIN PERFUSION; CHOLINERGIC ACTIVITY; DIFFUSE LEWY BODY DISEASE; FRONTAL CORTEX; FRONTOTEMPORAL DEMENTIA; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HUMAN; NEUROCHEMISTRY; NEUROPHARMACOLOGY; OXIDATIVE STRESS; REVIEW; SEROTONINERGIC SYSTEM; TEMPORAL CORTEX; BRAIN CIRCULATION; DEMENTIA; FRONTAL LOBE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TEMPORAL LOBE;

CEREBROVASCULAR CIRCULATION; DEMENTIA; DOPAMINE; FRONTAL LOBE; GLUCOSE; HUMANS; NEUROCHEMISTRY; NEUROPHARMACOLOGY; OXIDATIVE STRESS; SEROTONIN; TEMPORAL LOBE;

EID: 33750111085     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4209.2005221     Document Type: Review

References (93)

1. Rosen HJ, Lengenfelder J, Miller B. Frontotemporal dementia. Neurol Clin 2000; 18: 979-92.
2. López-Pousa S. Demencias frontales. Barcelona: Prous Science; 2001. 3. Muñoz DG. Neuropatología de la demencia frontotemporal. Neurologia 2000; 15 (Supl 1): S2-8.
3. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology 2002; 58: 1615-21.
4. Gislason TB, Sjogren M, Larsson L, Skoog I. The prevalence of frontal variant frontotemporal dementia and the frontal lobe syndrome in a population based sample of 85 year olds. J Neurol Neurosurg Psychiatry 2003; 74: 867-71.
5. Rosso SM, Donker-Kaat L, Baks T, Joosse M, De-Koning I, Pijnenburg Y, et al. Frontotemporal dementia in the Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain 2003; 126: 2016-22.
6. Rosso SM, Landweer EJ, Houterman M, Donker-Kaat L, Van Duijn CM, Van-Swieten JC. Medical and environmental risk factors for sporadic frontotemporal dementia: a retrospective case-control study. J Neurol Neurosurg Psychiatry 2003; 74: 1574-6.
7. Del-Ser T. Manifestaciones clínicas de la demencia frontotemporal. Neurologia 2000; 15 (Supl 1): S9-16.
8. The Lund and Manchester Groups. Consensus statement. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994; 57: 416-8.
9. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-54.
10. Jackson M, Lowe J. The new neuropathology of degenerative frontotemporal dementias. Acta Neuropathol (Berl) 1996; 91: 127-34.
11. Wilhemsen KC, Lynch T, Pavlou E, Higgins M, Nygaard TG. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am J Hum Genet 1994; 55: 1159-65.
12. Yamaoka LH, Welsh-Bohmer KA, Hulette CM, Gaskell PC Jr, Murray M, Rimmler JL, et al. Linkage of frontotemporal dementia to chromosome 17: clinical and neuropathological characterization of phenotype. Am J Hum Genet 1996; 59: 1306-12.
13. Heutink P, Stevens M, Rizzu P, Bakker E, Kros JM, Tibben A, et al. Hereditary frontotemporal dementia is linked to chromosome 17q21-q22: a genetic and clinicopathological study of three dutch families. Ann Neurol 1997; 41: 150-9.
14. Foster NL, Wilhelmsen K, Sima AA, Jones MZ, D'Amato CJ, Gilman S. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol 1997; 41: 706-15.
15. Spillantini MG, Van-Swieten JC, Goedert M. Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Neurogenetics 2000; 2: 193-205.
16. Stanford PM, Shepherd CE, Halliday GM, Brooks WS, Schofield PW, Brodaty H, et al. Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia. Brain 2003; 126: 814-26.
17. Binetti G, Nicosia F, Benussi L, Ghidoni R, Feudatari E, Barbiero L, et al., Prevalence of TAU mutations in an italian clinical series of familial frontotemporal patients. Neurosci Lett 2003; 338: 85-7.
18. Sobrido MJ, Miller BL, Havlioglu N, Zhukareva V, Jiang Z, Nasreddine ZS, et al. Novel tau polymorphisms, tau haplotypes, and splicing in familial and sporadic frontotemporal dementia. Arch Neurol 2003; 60: 698-702.
19. Stanford PM, Brooks WS, Teber ET, Hallupp M, McLean C, Halliday GM, et al. Frequency of tau mutations in familial and sporadic frontotemporal dementia and other taupathies. J Neurol 2004; 251: 1098-104.
20. Levchenko A, Robitaille Y, Strong MJ, Rouleau GA. Tau mutations are not a predominant cause of frontotemporal dementia in Canadian patients. Can J Neurol Sci 2004; 31: 363-7.
21. Brown J. Chromosome 3-linked frontotemporal dementia. Cell Mol Life Sci 1998; 54: 925-7.
22. Ashworth A, Lloyd S, Brown J, Gydesen S, Sorensen SA, Brun A, et al. Molecular genetic characterization of frontotemporal dementia on chromosome 3. Dement Geriatr Cogn Disord 1999; 10 (Suppl 1): 93-101.
23. Yancopoulou D, Crowther RA, Chakrabarti L, Gydesen S, Brown JM, Spillantini MG. Tau protein in frontotemporal dementia linked to chromosome 3 (FTD-3). J Neuropathol Exp Neurol 2003; 62: 878-82.
24. Tang-Wai D, Lewis P, Boeve B, Hutton M, Golde T, Baker M, et al. Familial frontotemporal dementia associated with a novel presenilin-1 mutation. Dement Geriatr Cogn Disord 2002; 14: 13-21.
25. Dermaut B, Kumar-Singh S, Engelborghs S, Theuns J, Rademakers R, Saerens J, et al. A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. Ann Neurol 2004; 55: 617-26.
26. Kalman J, Juhasz A, Majtenyi K, Rimanoczy A, Jakab K, Gardian G, et al. Apolipoprotein E polymorphism in Pick's disease and in Huntington's disease. Neurobiol Aging 2000; 21: 555-8.
27. Ingelson M, Fabre SF, Lilius L, Andersen C, Viitanen M, Almkvist O, et al. Increased risk for frontotemporal dementia through interaction between tau polymorphisms and apolipoprotein E epsilon4. Neuroreport 2001; 12: 905-9.
28. Emanuele E, Peros E, Tomaino C, Feudatari E, Bernardi L, Binetti G, et al. Association between small apolipoprotein(a) isoforms and frontotemporal dementia in humans. Neurosci Lett 2003; 353: 201-4.
29. Johansson A, Hampel H, Faltraco F, Buerger K, Minthon L, Bogdanovic N, et al. Increased frequency of a new polymorphism in the cell division cycle 2 (cdc2) gene in patients with Alzheimer's disease and frontotemporal dementia. Neurosci Lett 2003; 340: 69-73.
30. Nielsen AS, Ravid R, Kamphorst W, Jorgensen OS. Apolipoprotein E epsilon 4 in an autopsy series of various dementing disorders. J Alzheimers Dis 2003; 5: 119-25.
31. Nagaoka S, Arai H, Iwamoto N, Ohwada J, Ichimiya Y, Nakamura M, Inoue R. A juvenile case of frontotemporal dementia: neurochemical and neuropathological investigations. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 1251-61.
32. Yang Y, Schmitt HP. Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation. Immunocytochemical and quantitative study using a graph method. Acta Neuropathol (Berl) 2001; 101: 256-70.
33. Procter AW, Qurne M, Francis PT. Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord 1999; 10 (Suppl 1): S80-4.
34. Engelborghs S, Vloeberghs E, Maertens K, Marescau B, De Deyn PP. Evidence for an association between the CSF HVA: 5-HIAA ratio and aggressiveness in frontotemporal dementia but not in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1080.
35. Kim SH, Krapfenbauer K, Cheon MS, Fountoulakis M, Cairns NJ, Lubec G. Human brain cytosolic histamine-N-methyltransferase is decreased in Down syndrome and increased in Pick's disease. Neurosci Lett 2002; 321: 169-72.
36. Sjogren M, Minthon L, Passant U, Blennow K, Wallin A. Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. Neurobiol Aging 1998; 19: 379-84.
37. Odawara T, Shiozaki K, Iseki E, Hino H, Kosaka K. Alterations of muscarinic acetylcholine receptors in atypical Pick's disease without Pick bodies. J Neurol Neurosurg Psychiatry 2003; 74: 965-7.
38. Wallin A, Sjogren M, Blennow K, Davidsson P. Decreased cerebrospinal fluid acetylcholinesterase in patients with subcortical ischemic vascular dementia. Dement Geriatr Cogn Disord 2003; 16: 200-7.
39. Nilsson CL, Brinkmalm A, Minthon L, Blennow K, Ekman R. Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Peptides 2001; 22: 2105-12.
40. Minthon L, Edvinsson L, Gustafson L. Correlation between clinical characteristics and cerebrospinal fluid neuropeptide Y levels in dementia of the Alzheimer type and frontotemporal dementia. Alzheimer Dis Assoc Disord 1996; 10: 197-203.
41. Minthon L, Edvinsson L, Gustafson L. Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia. Dement Geriatr Cogn Disord 1997; 8: 232-9.
42. Bettendorff L, Mastrogiacomo F, Wins P, Kish SJ, Grisar T, Ball MJ. Low thiamine diphosphate levels in brains of patients with frontal lobe degeneration of the non-Alzheimer's type. J Neurochem 1997; 69: 2005-10.
43. Ferrer I, Marin C, Rey MJ, Ribalta T. Brain-derived neurotrophic factor in patients with frontotemporal dementia. Neurosci Lett 2000; 279: 33-6.
44. Ernst T, Chang L, Melchor R, Mehringer CM. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 1997; 203: 829-36.
45. Kizu O, Yamada K, Nishimura T. Proton chemical shift imaging in pick complex. AJNR Am J Neuroradiol 2002; 23: 1387-92.
46. Arai H, Morikawa Y, Higuchi M, Matsui T, Clark CM, Miura M, et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun 1997; 236: 262-4.
47. Green AJ, Harvey RJ, Thompson EJ, Rossor MN. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett 1999; 259: 133-5.
48. Molina L, Touchon J, Herpe M, Lefranc D, Duplan L, Cristol JP, Sabatier R. Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias. Neuroreport 1999; 10: 3491-5.
49. Fabre SF, Forsell C, Viitanen M, Sjogren M, Wallin A, Blennow K, et al. Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon4 frequency, but no tau gene mutations. Exp Neurol 2001; 168: 413-38.
50. Rosso SM, Van Herpen E, Pijnenburg YA, Schoonenboom NS, Scheltens P, Heutink P, et al. Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. Arch Neurol 2003; 60: 1209-13.
51. Sjogren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 2000; 54: 1960-4.
52. Sjogren M, Minthon L, Davidsson P, Granerus AK, Clarberg A, Vanderstichele H, et al. CSF levels of tau, beta-amyloid (1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 2000; 107: 563-79.
53. Sjogren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001; 70: 624-30.
54. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000; 285: 49-52.
55. Rosengren LE, Karlsson JE, Sjogren M, Blennow K, Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology 1999; 52: 109093.
56. Sjogren M, Davidsson P, Wallin A, Granerus AK, Grundstrom E, Askmark H, et al. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement Geriatr Cogn Disord 2002; 13: 112-8.
57. Andersen C, Jensen M, Lannfelt L, Lindau M, Wahlund LO. Amyloid Abeta40 CSF concentrations correlate to frontal lobe atrophy in frontotemporal dementia. Neuroreport 2000; 11: 287-90.
58. Sjogren M, Flokesson S, Blennow K, Tarkowski E. Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications. J Neurol Neurosurg Psychiatry 2004; 75: 1107-11.
59. Green AJ, Harvey RJ, Thompson EJ, Rossor MN. Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia. Neurosci Lett 1997; 235: 5-8.
60. Davidsson P, Sjogren M, Andreasen N, Lindbjer M, Nilsson CL, Westman-Brinkmalm A, Blennow K. Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Res Mol Brain Res 2002; 109: 128-33.
61. Sáez-Valero J, Costell M, Sjogren M, Andreasen N, Blennow K, Luque JM. Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's disease. J Neurosci Res 2003; 72: 132-6.
62. Diamandis EP, Scorilas A, Kishi T, Blennow K, Luo LY, Soosaipillai A, et al. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Clin Biochem 2004; 37: 230-7.
63. Kimura M, Asada T, Uno M, Machida N, Kasuya K, Taniguchi Y, et al. Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease. Neurosci Lett 1999; 273: 137-9.
64. Short RA, Bowen RL, O'Brien PC, Graff-Radford NR. Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc 2001; 76: 906-09.
65. Engelborghs S, Vloeberghs E, Maertens K, Marien P, Somers N, Symons A, et al. Correlations between cognitive, behavioural and psychological findings and levels of vitamin B12 and folate in patients with dementia. Int J Geriatr Psychiatry 2004; 19: 365-70.
66. Sjogren M, Gustafson L, Wikkelso C, Wallin A. Frontotemporal dementia can be distinguished from Alzheimer's disease and subcortical white matter dementia by an anterior-to-posterior rCBF-SPET ratio. Dement Geriatr Cogn Disord 2000; 11: 275-85.
67. Charpentier P, Lavenu I, Defebvre L, Duhamel A, Lecouffe P, Pasquier F, et al. Alzheimer's disease and frontotemporal dementia are differentiated by discriminant analysis applied to (99m)Tc HmPAO SPECT data. J Neurol Neurosurg Psychiatry 2000; 69: 661-3.
68. Steinling M, Defebvre L, Duhamel A, Lecouffe P, Lavenu I, Pasquier F, et al. Is there a typical pattern of brain SPECT imaging in Alzheimer's disease?. Dement Geriatr Cogn Disord 2001; 12: 371-8.
69. Uterga JM, Rodríguez-Iriarte ML, González-García AI, Taramundi S, Álvaro LC, Cortina C. Demencia con atrofia del lóbulo frontal: estudio clínico de 18 pacientes con deterioro cognitivo y afectación del lóbulo frontal detectada por neuroimagen estructural y funcional. Rev Neurol 2002; 34: 709-14.
70. Varrone A, Pappata S, Caraco C, Soricelli A, Milan G, Quarantelli M, et al. Voxel-based comparison of rCBF SPET images in frontotemporal dementia and Alzheimer's disease highlights the involvement of different cortical networks. Eur J Nucl Med Mol Imaging 2002; 29: 1447-54.
71. Kanako K, Kuwabara Y, Sasaki M, Ogomori K, Ichimiya A, Koga H, et al. Posterior cingulate hypoperfusion in Alzheimer's disease, senile dementia of Alzheimer type, and other dementias evaluated by three-dimensional stereotactic surface projections using Tc-99m HMPAO SPECT. Clin Nucl Med 2004; 29: 362-6.
72. Ishii K, Sakamoto S, Sasaki M, Kitagaki H, Yamaji S, Hashimoto M, et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med 1998; 39: 1875-8.
73. Grimmer T, Diehl J, Drzezga A, Forstl H, Kurz A. Region-specific decline of cerebral glucose metabolism in patients with frontotemporal dementia: a prospective F-FDG-PET study. Dement Geriatr Cogn Disord 2004; 18: 32-6.
74. Garraux G, Salmon E, Degueldre C, Lemaire C, Franck G. Medial temporal lobe metabolic impairment in dementia associated with motor neuron disease. J Neurol Sci 1999; 168; 145-50.
75. Diehl J, Grimmer T, Drzezga A, Riemenschneider M, Forstl H. Kurz A. Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia. A PET study. Neurobiol Aging 2004; 25: 1051-6.
76. Santens P, De-Bleecker J, Goethals P, Strijckmans K, Lemahieu I, Slegers G, et al. Differential regional cerebral uptake of (18)F-fluoro-2-deoxy-D- glucose in Alzheimer's disease and frontotemporal dementia at initial diagnosis. Eur Neurol 2001; 45: 19-27.
77. Salmon E, Garraux G, Delbeuck X, Collette F, Kalbe E, Zuendorf G, et al. Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia. Neuroimage 2003; 20: 435-40.
78. Pal PK, Wszolek ZK, Kishore A, De-la-Fuente-Fernandez R, Sossi V, Uitti RJ, et al. Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal dementia with parkinsonism linked to chromosome 17 and point mutation in tau gene). Parkinsonism Relat Disord 2001; 7: 81-8.
79. Rinne JO, Laine M, Kaasinen V, Norvasuo-Heila MK, Nagren K, Helenius H. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology. 2002; 58: 1489-93.
80. Hartzler AW, Zhu X, Siedlak SL, Castellani RJ, Avila J, Perry G, et al. The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidativ e stress, and tau. Neurobiol Aging 2002; 23: 855-9.
81. Puig B, Viñals F, Ferrer I. Active stress kinase p38 enhances and perpetuates abnormal tau phosphorylation and deposition in Pick's disease. Acta Neuropathol (Berl) 2004; 107: 185-9.
82. Horiguchi T, Uryu K, Giasson BI, Ischiropoulos H, LightFoot R, Bellmann C, et al. Nitration of tau protein is linked to neurodegeneration in tauopathies. Am J Pathol 2003; 163: 1021-31.
83. Su JH, Nichol KE, Sitch T, Sheu P, Chubb C, Miller BL, et al. DNA damage and activated caspase-3 expression in neurons and astrocytes: evidence for apoptosis in frontotemporal dementia. Exp Neurol 2000; 163: 9-19.
84. Giannakopoulos P, Kovari E, Savioz A, De-Bilbao F, Dubois-Dauphin M, Hof PR, et al. Differential distribution of presenilin-1, Bax, and Bcl-X(L) in Alzheimer's disease and frontotemporal dementia. Acta Neuropathol (Berl) 1999; 98: 141-9.
85. Nichol KE, Kim R, Cotman CW. Bcl-2 family protein behavior in frontotemporal dementia implies vascular involvement. Neurology 2001; 56 (Suppl 4): S35-40.
86. Yao Y, Zhukareva V, Sung S, Clark CM, Rokach J, Lee VM, et al. Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia. Neurology 2003; 61: 475-8.
87. Grazina M, Silva F, Santana I, Santiago B, Mendes C, Simoes M, et al. Frontotemporal dementia and mitochondrial DNA transitions. Neurobiol Dis 2004; 15: 306-11.
88. Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997; 58: 212-6.
89. Lebert F, Stekke W, Hasenbroeckx C, Pasquier F. Frontotemporal dementia: a randomized, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004; 17: 355-9.
90. Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl) 2004; 172: 400-8.
91. Robles-Bayón A. Demencia frontotemporal: posibilidades terapéuticas. Neurologia 2000; 15 (Supl 1): S38-42.
92. Allain H, Bentue-Ferrer D, Tribut O, Merienne M, Belliard S. Drug therapy of frontotemporal dementia. Hum Psychopharmacol 2003; 18: 221-5.
93. Levine AJ, Hewett L. Estrogen replacement therapy and frontotemporal dementia. Maturitas 2003; 45: 83-8.